Literature DB >> 9974153

Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration.

B M Morrison1, J H Morrison.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurologic disease that rapidly progresses from mild motor symptoms to severe motor paralysis and premature death. Until recently, there were few substantive studies conducted on the pathogenesis of the disease. With the genetic linkage of mutations in the superoxide dismutase (SOD-1) gene with familial ALS patients, new avenues for study have become available including transgenic mice and culture models. Although not yet providing a complete picture of the disease mechanism, studies utilizing these model systems have greatly advanced our understanding of the mechanism of degeneration and should eventually lead to putative therapeutic agents. In this review, we will present the important findings from these model systems, provide a framework in which to evaluate these findings, and speculate on the mechanism of degeneration initiated by the mutations in SOD-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9974153     DOI: 10.1016/s0165-0173(98)00049-6

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  19 in total

1.  Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease.

Authors:  B K Vanselow; B U Keller
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

2.  Characterization of the Mitochondrial Aerobic Metabolism in the Pre- and Perisynaptic Districts of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Silvia Ravera; Tiziana Bonifacino; Martina Bartolucci; Marco Milanese; Elena Gallia; Francesca Provenzano; Katia Cortese; Isabella Panfoli; Giambattista Bonanno
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

3.  The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis.

Authors:  Frank O Johnson; William D Atchison
Journal:  Neurotoxicology       Date:  2009-07-24       Impact factor: 4.294

Review 4.  Need for a paradigm shift in therapeutic approaches to CNS injury.

Authors:  Bharath Wootla; Aleksandar Denic; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2012-04       Impact factor: 4.618

5.  Activation of a glycine transporter on spinal cord neurons causes enhanced glutamate release in a mouse model of amyotrophic lateral sclerosis.

Authors:  Luca Raiteri; Egle Paolucci; Simona Prisco; Maurizio Raiteri; Giambattista Bonanno
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 6.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  Adrenal dysregulation in amyotrophic lateral sclerosis.

Authors:  F R Patacchioli; P Monnazzi; A Scontrini; E Tremante; I Caridi; E Brunetti; F R Buttarelli; F E Pontieri
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

9.  The kinesin superfamily protein KIF17: one protein with many functions.

Authors:  Margaret T T Wong-Riley; Joseph C Besharse
Journal:  Biomol Concepts       Date:  2012-06-01

10.  Specific electron transport chain abnormalities in amyotrophic lateral sclerosis.

Authors:  Jerry Lin; Andrew Diamanduros; Soheli A Chowdhury; Stephen Scelsa; Norman Latov; Saud A Sadiq
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.